You are here

  • Home
  • Archive
  • Volume 92, Issue 2
  • Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability

Citation Tools

Article menu
Download PDFPDF
Letter
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Mulka L, Annandale D, Richardson C, et al
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
Sexually Transmitted Infections 2016;92:107.